Begum Gorgulu Akin

Dr. Begum Gorgulu Akin

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2018 in World Allergy Organization Journal
Verified
Journal Article
Open access
ZSZeynep Celebi Sözener
Zeynep Celebi Sözener
BABegum Gorgulu Akin
Begum Gorgulu Akin
DMDilsad Mungan
Dilsad Mungan
BSBetul Ayse Sin
Betul Ayse Sin
ZMZeynep Misirligil
Zeynep Misirligil
SBSevim Bavbek
Sevim Bavbek
Data are limited regarding the effectiveness of omalizumab in patients with eosinophilic granulomatosis with polyangiitis (EGPA). Our aim was to evaluate the clinical and functional effectiveness of omalizumab in patients with EGPA in long-term follow-up. This study was a retrospective chart review of patients with EGPA who were treated with omalizumab injections between May 2012 and April 2018. Once treatment with omalizumab was started, data were collected at various time points: baseline, the 16th week, 1st year, and annually until the last evaluation. Eighteen patients (16F/2M) with a mean age of 48.61 ± 11.94 years were included. Data were available for all patients for the first year, 12 patients for the second year, 10 patients for the third year, 8 patients for the fourth year and 5 patients for the fifth year. All patients were on mean dosage of 15.77 ± 7.6 mg/day oral corticosteroid (OCS) as daily bases for mean 8.61 ± 4 years besides high-dose inhaler corticosteroid/long-acting beta agonist. Antineutrophil cytoplasmic antibodies (ANCA) were positive in 2 patients, and 8 patients were diagnosed as having vasculitis by skin biopsy, one patient had polyneuropathy, and one patient had cardiac involvement.By considering the individual responses of patients and the level of improvement at the last evalulation, 10 (55.6%) patients responded completely, 1 responded partially, and 7 (38.9%) had no improvement. Omalizumab worked as a steroid-sparing agent in all patients and the daily OCS dose was reduced with a mean dosage of 6.28 mg/day at the end of the first year. The mean OCS reduction time for the whole group was 4 months. A reduction in asthma exacerbations/hospitalizations, improvement in forced expiratory volume in 1 second, and no decrease in the eosinophil count during treatment with omalizumab were also observed. Omalizumab improved asthma control in some patients with EGPA with uncontrolled asthma by reducing asthma exacerbations and oral steroid requirement. However, more data are needed before recommending widespread use of omalizumab in patients with EGPA.

20 December 2021 in World Allergy Organization Journal
Verified
Journal Article
Open access
BABegum Gorgulu Akin
Begum Gorgulu Akin
MEMerve Erkoc
Merve Erkoc
EKElif Tugce Korkmaz
Elif Tugce Korkmaz
BOBetul Ozdel Ozturk
Betul Ozdel Ozturk
SCSevgi Colak
Sevgi Colak
SBSevim Bavbek
Sevim Bavbek
All platin-based chemotherapeutics can cause hypersensitivity reactions (HSRs). With rapid drug desensitization (RDD), few patients experience breakthrough reactions (BTR) during desensitization. However, data about risk factors for BTRs during RDD in patients with HSRs to platins are limited. We first aimed to describe characteristics of our platin-reactive population and to validate the Brigham and Women's Hospital's (BWH's) RDD protocol in our population along with their outcomes with RDD. Our second aim was to identify the risk factors for BTRs. This was a retrospective chart review (2013–2020) of patients with symptoms of immediate HSRs to platins. Initial HSRs were classified as grade 1, 2, or 3 based on their severity. Skin prick tests (SPT)/intradermal tests (IDT) were performed with implicated platins. A 12-step protocol was used during RDD. The study comprised 65 women and seven men (mean age 57.78 ± 8.73 years). Initial HSRs to carboplatin, cisplatin, and oxaliplatin occurred in 38, 13, and 21 patients, respectively. All patients reacted at the fifth (median) recurrent infusions (min:1, max:20). The median values for carboplatin, cisplatin, and oxaliplatin were 6 (1–20), 3 (1–15), and 3 (1–11), respectively. Most initial HSRs were grade 2 (n = 40, 55.6%) and 3 (n = 27, 37.5%); only 6.9% (n = 5) were grade 1. Patients with grade 1, 2, and 3 initial HSRs had positive platin skin test results at rates of 80%, 74%, and 88%, respectively. A total of 232 RDDs were performed in 72 patients and 98.7% of these desensitizations were completed. BTRs occurred in 56 (24.1%) (grade 1 n = 14, 25%; grade 2 n = 32, 57%; grade 3 n = 10, 18%) of these desensitizations. Breakthrough reactions were more severe in patients with positive SPTs or 1:100 or 1:10 dilutions of IDT (p = 0.014). BTR was not observed during RDD in any of the patients with positive 1:1 dilutions of IDT. Positivity on prick or 1:100 or 1:10 IDT increased the risk of BTR 5.058 times. There was no significant association between the risk of BTRs and age, drug cycle, sex, comorbidities, or atopy. In our experience, 98.7% of 232 RDDs to platins were completed successfully, showing that RDD was safe and effective. Drug skin test positivity is a potential marker for identifying high-risk patients who will have BTRs during RDDs to platins.

21 October 2024 in Clinical and Translational Allergy
Verified
Journal Article
Open access
DEDöne Gülçin Unutmaz Erkaya
Döne Gülçin Unutmaz Erkaya
MDMakbule seda bayrak durmaz
Makbule seda bayrak durmaz
BABegum Gorgulu Akin
Begum Gorgulu Akin
SBSevim Bavbek
Sevim Bavbek
Background: Following the increased use of biological agents, a subset of patients experiences hypersensitivity reaction (HSR). We reported our experience with rapid drug desensitization (RDD) to nine biologics (rituximab, infliximab, cetuximab, trastuzumab, pertuzumab, nivolumab, brentuximab, tocilizumab and filgrastim) and identified risk factors for breakthrough reactions (BTRs).Method: This was a retrospective review (2013–2022) of patients with immediate HSRs to biological agents. Initial HSRs were classified as grade 1, 2, or 3 in their severity. Skin prick tests (SPT)/intradermal tests (IDT) were performed using implicated agents. The phenotypes of HSRs were defined as Type I, cytokine‐release syndrome (CRS), mixed reactions (cytokine‐release + type I) based on history, clinical presentations and skin tests with implicated biologicals. A 12‐step RDD protocol was used.Results: The study comprised 45 patients (F/M: 31/14, median age: 55 (range: 20–69)). Majority of the patients reacted at the first infusion (n: 29/45, 64.4%). The majority of initial HSRs were grade 3 (n: 24/45, 53.3%) and grade 2 (n: 21/45, 46.6%); none were grade 1. Initial reactions were presented as type I (n: 20/45, 44.4%), CRS (n: 12/45, 26.6%) and mixed (n: 13/45, 28.8%). A total of 258 RDDs were performed and 98.4% of them were completed successfully. BTRs occurred in 36/258 (13.9%) infusions of RDDs. There was no significant association between the BTRs and age, drug cycle, SPT and IDT positivity, gender, comorbidities, or atopy.Conclusion: In our experience, 98.4% of 258 RDDs to biologics were successfully completed; RDD was safe and effective for our population.

23 February 2025 in Medicina
Verified
Journal Article
Open access
PDF file
BABegum Gorgulu Akin
Begum Gorgulu Akin
BÖBetül Özdel Öztürk
Betül Özdel Öztürk
MDMakbule seda bayrak durmaz
Makbule seda bayrak durmaz
OAOzge OZTURK AKTAS
Ozge OZTURK AKTAS
ŞSŞadan Soyyiğit
Şadan Soyyiğit
Background and Objectives: Early-type drug hypersensitivity reactions (DHRs) are observed within the first 1–6 h and most commonly manifest as urticaria and/or angioedema. Detailed anamnesis, skin prick tests (SPTs), intradermal tests (IDTs), and oral/intramuscular/intravenous drug provocation tests (DPTs) can be used to identify the drug responsible. We aimed to evaluate the demographic characteristics, responsible drugs, DHR types, and DPT results used in the diagnosis of drug allergy in patients who presented to our clinic with suspected drug allergies. Materials and Methods: The medical records of patients who presented with a suspicion of an early-type DHR between February 2019 and December 2024 were retrospectively evaluated through the hospital information management system. A total of 188 adults who underwent diagnostic drug testing were included. Results: The diagnosis of drug allergy was confirmed in 51 (27%) patients. In 137 (73%) patients, the diagnosis of drug allergy was excluded after DPTs. In 78 of the 188 patients, there was a DHR to a single suspected drug. The other 110 patients had DHR histories with multiple drugs. The rate of confirmation of a drug allergy from diagnostic tests was higher in those who described a history of multiple drug allergies. Amongst the antibiotics, beta-lactam antibiotics (n = 47) were the most frequently suspected drugs. The rate of positive DPTs (n = 4; 8%) was lower in patients with suspected beta-lactam allergies than other antibiotics (p = 0.002). NSAIDs (n = 60) were the second most common group of suspected drug allergies. With regard to IgE or COX-1-mediated mechanisms, there was no statistically significant difference in DPT positivity among these NSAIDs (p = 0.414). The severity of the initial early-type DHRs were grade 1 (n = 168; 80%), grade 2 (n = 14; 7%), and grade 3 (n = 14; 7%). If the patients had redness, itching, urticaria, angioedema, dyspnea, cyanosis, desaturation, syncope, tachycardia, or hypotension during their initial DHRs, the positive diagnostic drug test rate was statistically significantly higher. However, experiencing diarrhea, nausea, and vomiting were not found to be associated with positive diagnostic drug tests. Drug allergies were confirmed with SPTs or IDTs in all patients in whom adrenaline was used during initial reactions. Conclusions: Contrary to the prevailing notion that drugs (especially beta-lactams) are the predominant cause of allergic reactions, this study demonstrated that the actual prevalence of drug allergies is, in fact, low.

31 May 2022 in Journal of Basic and Clinical Health Sciences
Verified
Journal Article
Closed access
AAAylin Ozgen Alpaydin
Aylin Ozgen Alpaydin
BABegum Gorgulu Akin
Begum Gorgulu Akin
SESelin Ercan
Selin Ercan
SÖSevgi Özalevli
Sevgi Özalevli
Background: Specific breathing exercises are reported to improve quality of life and reduce symptoms; although no significant benefit on lung function or reduction of exacerbation risk. Additionally, inspiratory muscle training (IMT) aims to increase diaphragm and inspiratory muscle endurance. In this regard, IMT has been studied in uncontrolled asthma patients to investigate its effect on respiratory symptoms and pulmonary functions. Methods: Twenty-one uncontrolled and partially controlled asthmatic patients were included in the study. Asthma control test (ACT), asthma quality of life questionnaire (AQLQ), and spirometric evaluations were performed. The study population was randomized into two groups. The standard care group (n=10) received standard medical treatment while the intervention (n=11) group practiced a portable threshold IMT device following standard medical treatment. Results: The study was completed by 15 patients due to 6 lost follow up (one intervention group and 5 standard care) and one asthma exacerbation. We have found that the intervention group tended to have increased pulmonary function test parameters and AQLQ scores, moreover; MIP values and ACT scores have statistically significant increases after IMT(p=0.01, p=0.02 respectively). Conclusion: Add-on IMT to standard medical treatment could improve asthma control by strengthening inspiratory muscles in uncontrolled asthmatic patients. IMT could be considered in the non-pharmacological treatments of uncontrolled asthmatic patients. Despite the limited number of patients, this study revealed that IMT might have positive outcomes for uncontrolled asthma patients.

23 October 2025 in Orphanet Journal of Rare Diseases
Verified
Journal Article
Open access
PDF file
MDMakbule seda bayrak durmaz
Makbule seda bayrak durmaz
BÖBetül Özdel Öztürk
Betül Özdel Öztürk
BABegum Gorgulu Akin
Begum Gorgulu Akin
FKFikriye handan Kalkan
Fikriye handan Kalkan
ŞSŞadan Soyyiğit
Şadan Soyyiğit
Background: Autoimmune thyroid diseases (AITDs) are among the most frequently reported autoimmune manifestations in individuals with inborn errors of immunity (IEIs). While immune dysregulation in IEI is known to predispose patients to autoimmunity, data regarding the prevalence and characteristics of AITD in this population remain limited. This study aimed to assess the frequency of AITD and describe its clinical, serological, ultrasonographic, and immunological features in a cohort of adult IEI patients. Methods: This retrospective study included 45 adult IEI patients, excluding those with selective IgA deficiency. Demographic, clinical, and immunological data were collected from medical records. AITD diagnosis was based on thyroid-specific autoantibodies, thyroid function tests, and/or ultrasonographic features consistent with thyroiditis. Comparative analyses were conducted between patients with and without AITD. Results: AITD was identified in 7 patients (15.5%), including 6 with Hashimoto’s thyroiditis (HT) and 1 with seronegative chronic autoimmune thyroiditis (SN-CAT); no cases of Graves’ disease were observed. The majority of patients with AITD were female (85.7%), while only one case occurred in a male (14.3%). No statistically significant sex-based difference in AITD frequency was detected ( p = 0.225). Anti-thyroid peroxidase antibodies were positive in 85.7% of AITD patients, and anti-thyroglobulin antibodies in 60.0%. All were euthyroid at evaluation, though 57.1% were receiving L-thyroxine therapy. Non-AITD thyroid abnormalities were present in 12 patients (26.6%), including isolated serology and a solitary thyroid nodule. Compared with non-AITD patients, those with AITD exhibited significantly higher CD16⁺56⁺ NK cell percentages ( p = 0.010), while other lymphocyte subsets did not differ. No significant differences were observed regarding sex, IEI phenotype, non-thyroidal autoimmunity, or infection-related complications. Conclusions: In this adult IEI cohort, HT was the most prevalent autoimmune thyroid condition. Distinct immunological features, particularly increased NK cell frequencies, may reflect underlying immune dysregulation. These findings support systematic thyroid evaluation, even in asymptomatic IEI patients, and emphasize the need for larger, genetically diverse cohorts to validate and expand these observations.